Georgina Long, Translational Research and Medical Oncology at the University of Sydney, shared a post on X about a recent article she and colleagues authored:
“Proud to lead this clinical trial, MORPHEUS, comparing different neoadjuvant (pre-surgery) immunotherapy combinations in stage III melanoma.
Shows how the neoadjuvant platform can deliver comparative clinical and translational data efficiently. anti-PD1+LAG3 and anti-PD1+CTLA4 are our most active combinations. TIGIT does not add.”
Title: Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Authors: Georgina V. Long, Nitya Nair, Daniel Marbach, Richard A. Scolyer, Sabine Wilson, Denise Cotting, Nicolas Staedler, Rodabe N. Amaria, Paolo Antonio Ascierto, Ahmad A. Tarhini, Caroline Robert, Omid Hamid, Caroline Gaudy-Marqueste, Celeste Lebbe, Eva Munoz-Couselo, Alexander M. Menzies, Cecile Pages, Giuseppe Curigliano, Mario Mandala, Nikki Jessop, Uwe Bader, Maurizio Perdicchio, Volker Teichgräber, Merlind Muecke, Christoph Markert, Christian Blank
Read the Full Article in Nature.
More posts featuring Georgina Long on OncoDaily.